DNA X, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $58.3M | $93.6M | $69.8M | $54.6M |
| Gross profit | — | $9.9M | $19.3M | $11.6M | $6.4M |
| Operating income | -$5.4M | -$3.1M | $513,000 | -$14.3M | -$38.0M |
| Operating expenses | $5.4M | $3.1M | $18.8M | $25.9M | $44.4M |
| Cost of revenue | — | $48.4M | $74.3M | $58.2M | $48.2M |
| Cash from operations | -$23.5M | -$8.5M | -$4.1M | -$12.4M | -$38.5M |
| Capital expenditure | — | $214,000 | $36,000 | $8,000 | $46,000 |
| Free cash flow | — | -$8.7M | -$4.1M | -$12.4M | -$38.5M |
| Impairments | $2.1M | $6.5M | — | — | — |
| Total assets | $43.9M | $39.7M | $56.0M | $53.7M | $41.1M |
| Total liabilities | $50.6M | $45.4M | $33.7M | $33.6M | $22.5M |
| Total debt | $5.7M | — | — | — | — |
Shares outstanding 1.5M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.